Philipneri M, Bastani B (fevereiro de 2001). «Kidney disease in patients with chronic hepatitis C». Curr Gastroenterol Rep. 3 (1): 79–83. PMID11177699. doi:10.1007/s11894-001-0045-0
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J (1988). «Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis». Hepatology. 8 (5): 1151–7. PMID2971015. doi:10.1002/hep.1840080532 !CS1 manut: Nomes múltiplos: lista de autores (link)
Martin PY, Ginès P, Schrier RW (agosto de 1998). «Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis». N. Engl. J. Med. 339 (8): 533–41. PMID9709047. doi:10.1056/NEJM199808203390807 !CS1 manut: Nomes múltiplos: lista de autores (link)
Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P; et al. (abril de 2002). «Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.». Gastroenterology (em inglês). 122 (4): 923-930. PMID11910344. doi:10.1053/gast.2002.32364 !CS1 manut: Nomes múltiplos: lista de autores (link)
Wong F, Blendis L (2001). «New challenge of hepatorenal syndrome: prevention and treatment». Hepatology. 34 (6): 1242–51. PMID11732014. doi:10.1053/jhep.2001.29200
Xu X, Ling Q, Zhang M; et al. (maio de 2009). «Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience». Transplantation. 87 (10): 1514–9. PMID19461488. doi:10.1097/TP.0b013e3181a4430b !CS1 manut: Nomes múltiplos: lista de autores (link)
Holt S, Goodier D, Marley R; et al. (1999). «Improvement in renal function in hepatorenal syndrome with N-acetylcysteine». Lancet. 353 (9149): 294–5. PMID9929029. doi:10.1016/S0140-6736(05)74933-3 !CS1 manut: Nomes múltiplos: lista de autores (link)
Wong F, Pantea L, Sniderman K (2004). «Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome». Hepatology. 40 (1): 55–64. PMID15239086. doi:10.1002/hep.20262 !CS1 manut: Nomes múltiplos: lista de autores (link)
Mitzner SR, Stange J, Klammt S; et al. (2000). «Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial». Liver Transpl. 6 (3): 277–86. PMID10827226. doi:10.1053/lv.2000.6355 !CS1 manut: Nomes múltiplos: lista de autores (link)
Witzke O, Baumann M, Patschan D; et al. (2004). «Which patients benefit from hemodialysis therapy in hepatorenal syndrome?». J. Gastroenterol. Hepatol. 19 (12): 1369–73. PMID15610310. doi:10.1111/j.1440-1746.2004.03471.x !CS1 manut: Nomes múltiplos: lista de autores (link)
Alessandria C, Ozdogan O, Guevara M; et al. (2005). «MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation». Hepatology. 41 (6): 1282–9. PMID15834937. doi:10.1002/hep.20687 !CS1 manut: Nomes múltiplos: lista de autores (link)
Wadei HM, Mai ML, Ahsan N, Gonwa TA (setembro de 2006). «Hepatorenal syndrome: pathophysiology and management». Clin J Am Soc Nephrol. 1 (5): 1066–79. PMID17699328. doi:10.2215/CJN.01340406 !CS1 manut: Nomes múltiplos: lista de autores (link)
Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME (1969). «Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease». N. Engl. J. Med. 280 (25): 1367–71. PMID4890476. doi:10.1056/NEJM196906192802501 !CS1 manut: Nomes múltiplos: lista de autores (link)
Ng CK, Chan MH, Tai MH, Lam CW. (fevereiro de 2007). «Hepatorenal syndrome». Clin Biochem Rev (em inglês). 28 (1): 11-17. PMID17603637 !CS1 manut: Nomes múltiplos: lista de autores (link)
Ginés P, Arroyo V, Quintero E; et al. (1987). «Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study». Gastroenterology. 93 (2): 234–41. PMID3297907 !CS1 manut: Nomes múltiplos: lista de autores (link)
Ginès A, Escorsell A, Ginès P; et al. (1993). «Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites». Gastroenterology. 105 (1): 229–36. PMID8514039 !CS1 manut: Nomes múltiplos: lista de autores (link)
Philipneri M, Bastani B (fevereiro de 2001). «Kidney disease in patients with chronic hepatitis C». Curr Gastroenterol Rep. 3 (1): 79–83. PMID11177699. doi:10.1007/s11894-001-0045-0
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J (1988). «Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis». Hepatology. 8 (5): 1151–7. PMID2971015. doi:10.1002/hep.1840080532 !CS1 manut: Nomes múltiplos: lista de autores (link)
Martin PY, Ginès P, Schrier RW (agosto de 1998). «Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis». N. Engl. J. Med. 339 (8): 533–41. PMID9709047. doi:10.1056/NEJM199808203390807 !CS1 manut: Nomes múltiplos: lista de autores (link)
Epstein M (abril de 1994). «Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy». J. Am. Soc. Nephrol. 4 (10): 1735–53. PMID8068872
Fernandez-Seara J, Prieto J, Quiroga J; et al. (1989). «Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure». Gastroenterology. 97 (5): 1304–12. PMID2676683 !CS1 manut: Nomes múltiplos: lista de autores (link)
Lenz K, Hörtnagl H, Druml W; et al. (1991). «Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor». Gastroenterology. 101 (4): 1060–7. PMID1832407 !CS1 manut: Nomes múltiplos: lista de autores (link)
Moore K, Ward PS, Taylor GW, Williams R (1991). «Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome». Gastroenterology. 100 (4): 1069–77. PMID2001805 !CS1 manut: Nomes múltiplos: lista de autores (link)
Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P; et al. (abril de 2002). «Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.». Gastroenterology (em inglês). 122 (4): 923-930. PMID11910344. doi:10.1053/gast.2002.32364 !CS1 manut: Nomes múltiplos: lista de autores (link)
Kaffy F, Borderie C, Chagneau C; et al. (janeiro de 1999). «Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients». J. Hepatol. 30 (1): 174. PMID9927168 !CS1 manut: Nomes múltiplos: lista de autores (link)
Wong F, Blendis L (2001). «New challenge of hepatorenal syndrome: prevention and treatment». Hepatology. 34 (6): 1242–51. PMID11732014. doi:10.1053/jhep.2001.29200
Xu X, Ling Q, Zhang M; et al. (maio de 2009). «Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience». Transplantation. 87 (10): 1514–9. PMID19461488. doi:10.1097/TP.0b013e3181a4430b !CS1 manut: Nomes múltiplos: lista de autores (link)
Holt S, Goodier D, Marley R; et al. (1999). «Improvement in renal function in hepatorenal syndrome with N-acetylcysteine». Lancet. 353 (9149): 294–5. PMID9929029. doi:10.1016/S0140-6736(05)74933-3 !CS1 manut: Nomes múltiplos: lista de autores (link)
Clewell JD, Walker-Renard P (1994). «Prostaglandins for the treatment of hepatorenal syndrome». Ann Pharmacother. 28 (1): 54–5. PMID8123962
Wong F, Pantea L, Sniderman K (2004). «Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome». Hepatology. 40 (1): 55–64. PMID15239086. doi:10.1002/hep.20262 !CS1 manut: Nomes múltiplos: lista de autores (link)
Mitzner SR, Stange J, Klammt S; et al. (2000). «Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial». Liver Transpl. 6 (3): 277–86. PMID10827226. doi:10.1053/lv.2000.6355 !CS1 manut: Nomes múltiplos: lista de autores (link)
Witzke O, Baumann M, Patschan D; et al. (2004). «Which patients benefit from hemodialysis therapy in hepatorenal syndrome?». J. Gastroenterol. Hepatol. 19 (12): 1369–73. PMID15610310. doi:10.1111/j.1440-1746.2004.03471.x !CS1 manut: Nomes múltiplos: lista de autores (link)
Alessandria C, Ozdogan O, Guevara M; et al. (2005). «MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation». Hepatology. 41 (6): 1282–9. PMID15834937. doi:10.1002/hep.20687 !CS1 manut: Nomes múltiplos: lista de autores (link)
Hecker R, Sherlock S (dezembro de 1956). «Electrolyte and circulatory changes in terminal liver failure». Lancet. 271 (6953): 1121–5. PMID13377688
Wadei HM, Mai ML, Ahsan N, Gonwa TA (setembro de 2006). «Hepatorenal syndrome: pathophysiology and management». Clin J Am Soc Nephrol. 1 (5): 1066–79. PMID17699328. doi:10.2215/CJN.01340406 !CS1 manut: Nomes múltiplos: lista de autores (link)
Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME (1969). «Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease». N. Engl. J. Med. 280 (25): 1367–71. PMID4890476. doi:10.1056/NEJM196906192802501 !CS1 manut: Nomes múltiplos: lista de autores (link)
